Is VIR stock safe? | Glauxie AI

Q: Is VIR stock safe?

Vir Biotechnology, Inc. (VIR) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Marianne De Backer. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a... Employees: 367.

Q: What are the risks of investing in VIR?

Identify key risks of investing in VIR — debt, competition, volatility, and sector headwinds.

Q: Is VIR a good long-term investment?

Evaluate VIR as a long-term investment using fundamental scores, growth metrics, and risk assessment.

Q: How much debt does VIR have?

Review VIR total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Is VIR stock safe?

🦉

Vir Biotechnology, Inc. (VIR)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOMarianne De Backer

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for...

Key Executives

Name	Title
Brent Sabatini	Senior Vice President, Principal Accounting Officer & Chief Accounting Officer
Carolyn Wang	Senior Vice President of Corporate Communications
Jason O'Byrne	Executive Vice President & Chief Financial Officer
Jennifer Eileen Towne	Executive Vice President & Chief Scientific Officer
Kiki Patel	Head of Investor Relations
Lawrence Corey	Co-Founder & Scientific Advisor

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

VIR Profile Financials

What are the risks of investing in VIR? Is VIR a good long-term investment? How much debt does VIR have?